PDCD1 and glioblastoma: Sub-stratification of patients revealed that no baseline characteristics of steroid use and MGMT methylated tumors (a prognostic feature in GBM) were associated with better survival in the Nivo-treated arm, but not the bevacizumab arm of the trial, possibly indicating the activity of a PD1 blockade in a subset of patients.